Yes. Shorts and criminals may use the same tactics they applied to DNDN. But, the outcome will be different. Our technology for both L & D is more advance than DNDN product and our manufacturing capability once EDEN becomes available would be in different category that DNDN couldn't match.
Yep, it certainly looks to be playing out that way.
Uhm, that might not be so good for longs.
DNDN ran a pair of P2 trials that were designed with PFS as the primary endpoint and OS as a secondary. The trials failed PFS but DNDN went to the FDA for approval based on OS and the FDA said no. It was another trial they started when they learned of the PFS/OS issue that when complete led to approval.
BTW, that twiitee you cite is clearly clueless. Neither of the two Car-T companies did anything over about a 2X gain on news.
Also, DNDN went from around $3 to around $20 on results (OS between randomizes arms in a propter trial). Then up to $60 or so in the months following approval. So post results, a 3 bagger.,
Market Data 
Markets 
AI
